Allergan Unanimously Rejects Valeant’s Bid

Allergan Unanimously Rejects Valeant’s Bid Play

May 12 (Bloomberg) -- Allergan board says the Valeant bid “substantially undervalues” the company and creates significant risks and uncertainties and is not in best interests of the company and shareholders. Tom Keene reports on Bloomberg Television’s “Bloomberg Surveillance.” (Source: Bloomberg)

  • On Air Now

    Market Makers Watch Now

  • Next

    Money Clip

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus